Phase 2, Efficacy and Safety Study of ACP-204 in Lewy Body Dementia Psychosis
← catalyst calendarNCT07029581 · readout ≤ 558 d
Sponsored by ACADIA Pharmaceuticals Inc. (industry) · ACAD — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
180estimated
Sites
59
Countries
Bulgaria, Czechia, France +3
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-08-06 | actual | When the study began enrolling |
| Primary completion | Feb 2028 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Mar 2028 | estimated | The whole study's end, after follow-up |
| First posted | 2025-06-19 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-24 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Lewy Body Dementia Psychosis
Interventions
- Drug: ACP-204
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFChange from Baseline in SAPS-LBDP total score at Week 6
measured 6 weeks
Permalink · ACAD's whole pipeline · Catalyst calendar · Every registered study · What changed